Vanda Patent-Cliff Exposure & CMS Drug Spending Portfolio

Vanda (US): 6 reconciled FDA prescription therapies, $242.4M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies6
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2031-01-01
2024 CMS Total Public Spend$242.4M
2024 Medicare Part D Spend$160.3M
2024 Medicaid Spend$82.0M
California HCAI SB 17 Filings4 WAC filings (max 18.4% 2-yr change)